Subsidy Information and Financing Scheme SDLSofosbuvir & Velpatasvir Tablet, Sofosbuvir 400 mg + Velpatasvir 100 mg
Drug Guidance for Subsidy 04/06/2024 Direct-acting antiviral agents for treating chronic hepatitis C The Ministry of Health’s Drug Advisory Committee has recommended: Sofosbuvir 400 mg/velpatasv... See all × 04/06/2024 Direct-acting antiviral agents for treating chronic hepatitis C The Ministry of Health’s Drug Advisory Committee has recommended: Sofosbuvir 400 mg/velpatasvir 100 mg tablets in line with its registered indications for treating chronic hepatitis C. Funding status RSofosbuvir 400 mg/velpatasvir 100 mg tablet is recommended for inclusion on the Standard Drug List (SDL) from 1 August 2024. NROf note, glecaprevir 100 mg/pibrentasvir 40 mg tablet will be delisted from the MOH List of Subsidised Drugs with effect from 1 February 2025.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet, Sofosbuvir 400 mg + Velpatasvir 100 mg Alexandra Hospital Changi General Hospital Khoo Teck Puat Hospital Ng Teng Fong General Hospital National University Hospital Sengkang General Hospital Singapore General Hospital Tan Tock Seng Hospital Woodlands Health Campus